Stockscreener 앱 받기
0.47%
시간 외 거래:
전일 마감가:
$29.58
열려 있는:
$29.305
하루 거래량:
20.52M
Relative Volume:
0.71
시가총액:
$167.80B
수익:
$63.32B
순이익/손실:
$7.52B
주가수익비율:
22.57
EPS:
1.3043
순현금흐름:
$9.48B
1주 성능:
+3.66%
1개월 성능:
+6.44%
6개월 성능:
+6.82%
1년 성능:
+20.11%
1일 변동 폭
$29.25
$29.69
1주일 범위
$28.55
$29.88
52주 변동 폭
$23.62
$29.88
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
29.44 | 167.80B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,240.34 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.79 | 611.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
282.68 | 499.53B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.63 | 354.36B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.20 | 285.49B | 54.66B | 13.58B | 16.05B | 7.0171 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-06 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2026-06-10 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Zacks Investment Research
Is Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) a Strong ETF Right Now? - Zacks Investment Research
Key facts: Pfizer Inc. expands oncology tie-up; raises dividend $0.43 - TradingView
Can Pfizer’s (NYSE:PFE) Earnings Support Its NYSE Composite Position? - Kalkine Media
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool
Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year - The Motley Fool
Micro Pfizer Inc Stock Futures, (XPFE0H27.CME) interactive stock chart - Yahoo Finance UK
Micro Pfizer Inc Stock Futures, (XPFE0H27.CME) latest stock news and headlines - Yahoo Finance UK
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool
PFIZER INC (PFE-USD.SW) cash flow - Yahoo Finance UK
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Pfizer Inc. (PFE.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - The Motley Fool
Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? - The Motley Fool
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance
What to Expect From Pfizer's Q3 2026 Earnings Report - Yahoo Finance
Lilly, Pfizer, J&J win EU drug recommendations this month - Seeking Alpha
PFIZER INC. R (PFE.DE) Q1 FY2025 earnings call transcript - Yahoo Finance
Layoffs Tracker: Kroger, Pfizer, Netflix and Amazon Hit This Week - Yahoo Finance
6 Blue Chip Stocks Trading Well Below Their Highs - The Motley Fool
Pfizer Inc. (PFE) latest press releases and corporate news - Yahoo Finance Australia
2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends - The Motley Fool
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Pfizer Stock Hits 52-Week High: What's Going On? - Benzinga
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Pfizer stock hits 52-week high at $29.88 - Investing.com
The Pfizer Foundation and the American Red Cross: Strengthening Communities Year-Round - American Red Cross
Pfizer, Thermo Fisher Scientific And More: CNBC’s ‘Final Trades’ - Benzinga
PFIZER INC (PFE-USD.SW) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Pfizer Inc (Coinbase Tokenized Stock) Price | PFEc Price Today, Live Chart, USD converter, Market Capitalization - CryptoRank
Pfizer (NYSE:PFE): What Changes After Its Latest Company Update? - Kalkine Media
Pfizer (PFE) Gains As Market Dips: What You Should Know - Zacks Investment Research
Pfizer (PFE) Gains As Market Dips: What You Should Know - Yahoo Finance
Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) Stock Historical Prices & DataYahoo Finance - Yahoo! Finance Canada
Micro Pfizer Inc Stock Futures, (XPFE0Z26.CME) latest stock news and headlines - Yahoo Finance UK
Pfizer Inc Stock (PFE) Moved Up by 3.14% on Oct 14: Drivers Behind the Movement - TradingKey
Pfizer cuts another 150 jobs at Portage plant as demand slips - Crain's Grand Rapids Business
Pfizer’s Next‑Gen Pneumococcal Shot Enters Key Phase 3 Test, Extending Vaccine Growth Potential - TipRanks
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026 - Business Wire
Pfizer partners with Enodia Therapeutics in $500m drug deal - Pharmaceutical Technology
PFEPfizer, Inc. | News - OTC Markets
Pfizer (PFE) Pays Out Over 226% of Earnings and Trades at 36.7x Trailing Against 9.8 Forward. What Is the Yield Telling You? - Yahoo Finance
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Reasons Why Investors Should Consider Betting on Arvinas Stock - Zacks Investment Research
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules - BioSpace
Pfizer: The Earnings Test That Matters (NYSE:PFE) - Seeking Alpha
Guggenheim reiterates Pfizer stock rating ahead of Q3 earnings - Investing.com
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
화이자 주식 (PFE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DAMICO JENNIFER B. | SVP & Controller |
Aug 05 '26 |
Sale |
25.40 |
3,278 |
83,261 |
28,611 |
| BLAYLOCK RONALD E | Director |
Aug 05 '26 |
Buy |
25.46 |
39,231 |
998,821 |
66,938 |
| Buckley Mortimer J | Director |
Aug 05 '26 |
Buy |
25.52 |
37,632 |
960,369 |
37,632 |
| DAMICO JENNIFER B. | SVP & Controller |
Jun 09 '26 |
Sale |
25.70 |
2,000 |
51,400 |
31,397 |
| SAHNI PAYAL | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
82,816 |
| LANKLER DOUGLAS M | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
122,907 |
4,156,715 |
282,186 |
| DAMICO JENNIFER B. | SVP & Controller |
Feb 25 '26 |
Option Exercise |
33.82 |
17,558 |
593,812 |
29,744 |
| BOURLA ALBERT | Chairman & CEO |
Feb 25 '26 |
Option Exercise |
33.82 |
491,626 |
16,626,791 |
864,215 |
| Fonseca Lidia | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
56,888 |
1,923,952 |
101,579 |
| McDermott Michael | Executive Vice President |
Feb 25 '26 |
Option Exercise |
33.82 |
37,925 |
1,282,624 |
114,534 |
1.06%
자본화:
|
볼륨(24시간):